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Abstract
Studies on host factors, particularly the APOBEC3G gene, have previously found an associ-
ation with AIDS progression in some populations and against some HIV-1 strains but not
others. Our study had two main objectives: firstly, to screen a population from Burkina Faso
for three variants of APOBEC3G previously described, and secondly to analyze the effect of
these three variants and their haplotypes on HIV-1 infection with Circulating Recombinant
Forms (CRFs) present in Burkina Faso. This case control study involved 708 seropositive
and seronegative individuals. Genotyping was done by the TaqMan allelic discrimination
method. Minor allele frequencies of rs6001417 (p<0.05), rs8177832 (P<0.05), and
rs35228531 (P<0.001) were higher in seronegative subjects. The rs6001417 and
rs8177832 SNPs were associated with HIV-1 infection in an additive model (P<0.01). Fur-
thermore the SNP rs35228531 was also associated with HIV-1 infection in a dominant
model (P<0.001). Odds ratio analysis of genotypes and alleles of the different APOBEC3G
variants showed that there is a strong association between theminor genetic variants,
genotype of the three SNPs, and HIV-1 status. Haplotype analysis demonstrated that
rs6001417, rs8177832, and rs35228531 are in linkage disequilibrium. The haplotype GGT
from the rs6001417, rs8177832 and rs35228531 respectively has a protective effect OR =
0.54 [0.43–0.68] with P<0.001. There was also associations between the haplotypes GGC
OR = 1.6 [1.1;-2.3] P<0.05, and CGC OR = 5.21 [2.4–11.3] P<0.001, which increase the
risk of infection by HIV-1 from almost two (2) to five (5) fold. This study demonstrates an
association of rs6001417, rs8177832, and rs35228531 of APOBEC3G with HIV-1 infection
in a population from Burkina Faso.
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Introduction
About 35 million people are living with HIV-1 worldwide at the end of 2013, with sub-Saharan
Africa paying the highest toll of this infection as it harbors 71% of infected persons worldwide
[1]. Phylogenetic studies conducted in Burkina Faso reported that Circulating Recombinant
Forms [CRF06_cpx 16/29 (55.17%), CRF02_AG 9/29 (31.03%), A1 2/29 (6.89%), G 1/29
(3.44%), and CRF09_cpx 1/29 (3.44%)] of the HIV-1 subtypes A, G, K, and J strains are pre-
dominant [2–7]. These CRFs or inter-subtypes are said to have originated from individuals
that were infected by different viruses of two or more subtypes, and are representative of HIV-
1 strains in West Africa. Most studies on vaccine development and host-pathogen interaction
that have been carried out extensively in the western world, for the development of new antire-
troviral therapies are mostly based on subtype B. Recently, efforts have been focused on the
host genetic factors that affect disease progression in HIV-1/AIDS [8,9] such as DC-SIGN,
CCR5, SAMHD1 and APOBEC3G. In fact, Apolipoprotein B mRNA editing enzyme catalytic
polypeptide-like 3G (APOBEC3G) is a potent host defense factor, which interferes with
Human Immunodeficiency Virus 1 (HIV-1) [10]. Vif or virion infectivity factor of HIV-1 is
able to counteract APOBEC3G antiviral activity by targeting it for degradation in proteasomes
[11, 12]. Vif proteins derived from subtypes A, B, CRF01_AE, and CRF_02AG in a study
showed non-significant but some-what differential anti-APOBEC3G activity levels based on
infectivity profiles while subtype C was highly significant [13, 14]. The APOBEC3G protein is
incorporated into newly synthesized viral particles, in the absence of the virion infectivity fac-
tor (vif), and hypermutates viral DNA by deamination of cytosine (C) to uracil (U). APO-
BEC3G polymorphisms, such as rs8177832 (H186R), are thought to be associated with HIV-1
subtype B and C pathogenesis in some ethnic groups [15, 16], though this association is not
seen in other populations [17,18]. These previous studies did not take into account the Circu-
lating Recombinant Forms of HIV-1, nor evaluate the effect of APOBEC3G polymorphisms in
West African ethnic groups.
In this study we screened a population from Burkina Faso for three variants of APOBEC3G
previously described. Additionally, we analyzed the effect of these three variants and their hap-
lotypes on HIV-1 infection with circulating recombinant forms present in Burkina Faso.
Materials and Methods
Study populations
The study group consisted of 336 seropositive and 372 seronegative individuals, for a total of
708. Both groups were recruited from the Saint Camille Hospital and the Pietro Annigoni Bio-
molecular Research Center (CERBA) cohorts and outpatients.
Sample collection, HIV-1 testing, CD4 T cell counts and plasma viral load
Plasma Samples obtained by venipuncture were tested for HIV-1 infection, using alere deter-
mine HIV-1/2 test, and the SD Bioline HIV-1/2 test was used to differentiate between HIV-1
and HIV-2. CD4 cells were enumerated using the BD FACSCount CD4 Reagent kit on a BD
FACS COUNT (Becton Dickinson, San Jose). Viral load was determined using the Abbott
HIV-1 Real Time Quantitative kit (Promega, USA) on the Abbottm2000rt (Abbot Laborato-
ries, Illinois) according to the manufacturer's protocol.
DNA extraction and genotyping
Genomic DNA was extracted from leucocytes using the "DNA Rapid Salting-Out" technique as
described by Miller et al. [19]. SNP selection was based on the most relevant APOBEC3G
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variants, rs8177832 (H186R), rs35228531 and rs6001417 described by [16]. The three markers
of APOBEC3G studied were genotyped using standard TaqMan SNP assays (ABI, Foster City,
CA) run on the 7500 Fast Real-Time PCR Systems (Life Technologies, California, USA).
Ethical considerations
Approval for the study was obtained from the National Health Ethic Committee. All study par-
ticipants or guardians gave their free written and informed consent.
Statistical analysis
SPSS version 20.0 was used for data analysis. Power-Marker software Version 3.25 was used for
the determination of the Hardy-Weinberg equilibrium and the calculation of allele and geno-
type frequencies. Changes were considered statistically significant at p< 0.05, using the Fisher
Exact test. Odds ratio (OR) and confidence intervals (CI) at 95% were calculated to estimate
the associations of HIV-1 infection with the rs6001417, H186R, and rs35228531 polymor-
phisms using Epi Info 7. Logistic regression was performed on all SNPs with statistically signif-
icant allele or genotype tests, associating additive, dominant and recessive models with minor
allele as the risk allele.
Linkage disequilibrium (LD) was characterized and haplotype frequencies were computed
using Power-marker[20], Haploview [21], and PHASE statistical software [22,23]. D’ and r2
summary statistics were calculated using Haploview [21]. Power Marker, Haploview and
PHASE use the Expectation Maximization (EM) algorithm to determine haplotype frequency
distributions in cases of unknown phase. Only haplotypes with a minimum frequency of 5%
were considered in the analysis.
Results
Our study seronegative and seropositive groups were composed respectively of 25% and 24%
of males, and females respectively 75% and 76%. The mean age of seropositive group was 30.11
+/- 14.85 years, while the mean age of the seronegative group was 27.14+/- 8.84; the median T
cell CD4 counts was 302 cells/mm3 (ranging from 4 to>2000 cells/mm3) with a median viral
load of 25121 copies/ml (ranging from non-detectable to 2 268 886 copies/ml).
The different allelic and genotypic frequencies of the three APOBEC3G loci for cases and
controls are listed respectively in Table 1. Results demonstrated that the three SNPs rs6001417,
rs8177832, and rs35228531 genotype, are all in Hardy-Weinberg equilibrium (HWE), as
shown in Table 1.
The three SNPs showed significant differences between cases and controls for both allelic
and genotypic distributions using a P-value of 0.05, as shown in Table 1.
There is a strong association between the minor genetic variant, genotype of the three SNPs,
and HIV-1 status. The rs6001417 G allele displays a protective effect with an OR = 0.78 [95%
CI 0.63–0.97, p = 0.022]. The effect seen for the allele, is caused by the effect seen for the homo-
zygous GG genotype with an OR = 0. 61 [95% CI: 0.41–0.09, p = 0.01]. For the rs8177832 SNP,
the G allele presents a protective effect, with an OR = 0.8 [95% CI 0.64–1, p = 0.035], due to the
effect seen for the homozygous GG genotype OR = 0.61 [95%CI: 0.41–0.09, P = 0.0]. The SNP
rs35228531 shows a stronger association with the HIV-1 status. The T allele displays a protec-
tive effect (reduces the risk of being infected) with an OR = 0.63 [95% [95% CI: 0.50–0.78,
p = 0.00003] caused by the effect observed for the homozygous TT genotype OR = 0.48 [95%
CI: 0.31–0.76, p = 0.001]. Conversely, the homozygous CC genotype almost doubles the risk of
being infected OR = 1.76 [95% CI: 1.26–2.38; p = 0.0005], the C allele also display the same pat-
tern: OR = 1.60 [95% CI: 1.28–1.99; p = 0.00003], (Table 1). For both rs8177832 and
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rs6001417, the major allele genotypes AA and CC did not show a significant association
(Table 1).
The multinomial logistic regression analysis for HIV-1 infection risk factors showed that in
the age groups 10–18, 19–30, and 31–45, there was a significant difference between the reparti-
tions of cases and controls, but these differences did not contribute to the risk of HIV-1 infec-
tion. For the genotype CC there was a significant difference of repartition between cases of
controls, the multinomial logistic regression analysis also demonstrated that the CC genotype
carriers had three (3) times the risk of being infected by HIV-1 OR = 3.38 [95% CI:1.503–
7.605], p = 0.003] (Table 2).
Our results seemed to show that for the association between 3 single loci and HIV-1 status,
based on additive, dominant and recessive models, the most significant genotype effect for
rs6001417 was an additive model OR = 1.68 [95% CI 1.78–2.40, p = 0. 005]. For the H186R
Table 1. Association between APOBEC3G polymorphisms and HIV-1 Status analysis.
SNP Cases (N = 336) Controls(N = 372) OR 95% CI Genotype p-value
rs6001417
CC 0.29 0.25 1.22 0.86–1.72 0.28
CG 0.54 0.49 0.98 0.73–1.32 0.94
GG 0.17 0.26 0.60 0.41–0.88 <0.01
Ga 0.443 0.505 0.78 0.63–0.97 <0.05
HWEb 0.072 0.748
rs8177832
AA 0.29 0.26 1.18 0.84–1.67 0.36
AG 0.54 0.49 1.21 0.89–1.64 0.24
GG 0.17 0.25 0.61 0.41–0.90 0.01
Ga 0.438 0.495 0.8 0.64–1 <0.05
HWEb 0.076 0.740
rs35228531
CC 0.45 0.32 1.73 1.26–2.38 <0.001
CT 0.44 0.48 0.85 0.63–1.16 0.32
TT 0.10 0.19 0.48 0.31–0.76 0.001
Ta 0.326 0.435 0.63 0.50–0.78 <0.0001
HWEb 0.784 0.678
a: Hardy-Weinberg Equilibrium
b: Minor allele
doi:10.1371/journal.pone.0146386.t001
Table 2. Multinomial logistic regression analysis for HIV-1 risk factors.
OR 95% CI p-value
0–9 years old 0.742 0.656–1.476 0.524
10–18 years old 0.26 0.119–0,570 0.001
19–30 years old 0.073 0.037–0.147 0.000
31–45 years old 0.353 0.173–0.717 .004
Sex 0.985 0.658–1.476 0.942
CC 3.381 1.503–7.605 0.003
OR: Odd ratio; CI: Conﬁdence interval; CC: genotype of the variant rs35228531
doi:10.1371/journal.pone.0146386.t002
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SNP rs8177832, the additive model A/A (referent) vs A/G, G/G OR = 1.651 [95% CI: 1.15–2.
37, p = 0. 008] was the most significant genotype, and finally the most significant genotype
effect for rs35228531 was the dominant model (CC vs. CT & TT), OR = 1.73 [95% CI 1.26–
2.38, p = 0.0005] (Table 3). The high degree of linkage disequilibrium (LD) seen between these
loci prevents us from determining whether each of the 3 loci has an independent effect on
HIV-1 status, however, so we further analyzed our data by haplotype construction.
Haplotype trend regression analysis was followed by LD and r2 analysis within the APO-
BEC3G gene using Haploview software (Fig 1). The linkage disequilibrium between rs6001417
and rs35228531 is very strong in both cases (D’ = 0.91) and controls (D’ = 0.97); their respec-
tive r2 values were 0.506 for cases and 0.715 for controls. There is also a strong linkage disequi-
librium between rs6001417 and rs8177832 for both cases (D’ = 0.755; r2 = 0.556) and controls
(D’ = 0.955, r2 = 0.874). LD for rs8177832 and rs35228531 was weaker for both cases (D’ =
0.7), and controls (D’ = 0.894) compared to the latter (Fig 1).
Haplotype frequencies were compared between cases and controls for the APOBEC3G
gene, using all 3 SNPs (Table 4). The p-value for the overall case-control comparison was 0.01,
indicating that the HIV-1+ and HIV-1- sets have significantly different haplotype distribu-
tions. This difference is apparently due to the higher frequency of the GGT haplotype in the
HIV-1 negative samples (41%) compared with the HIV-1 positive samples (28%) (Fig 2). For
the GGT genotype, there was a protective effect against HIV-1 infection with OR = 0.56 [95%
CI; 0.45–0.71, p<0.001] (Table 4). There were also associations between the genotypes GGC,
OR = 1.6 [95%CI 1.1–2.3, p<0.05], and CGC OR = 5.21 [95%CI: 2.4; 11.3, p<0.001], which
increase the risk of infection from almost two (2) to five (5) times by HIV-1 (Table 4).
The distribution of the case and control haplotypes is shown in Fig 2. The loci are shown in
the order: rs6001417- rs8177832- rs35228531. This represents the frequencies of the different
haplotypes present among cases (blue) and controls (orange). The differences were statistically
significant for the haplotypes shown as “” (p<0.05), and “” (p<0.001).
Discussion
We investigated the distribution of three genetic variations within the APOBEC3G gene in a
population from Burkina Faso, where the HIV-1 Circulating Recombinant Forms CRF06_cpx
and CRF02_AG dominate [2]. We studied the APOBEC3G gene regardless of the fact that Vif
or virion infectivity factor of HIV-1 is able to counteract APOBEC3G antiviral activity by tar-
geting it for degradation in proteasomes [11, 12]. Although HIV-1/AIDS affects Sub-Saharan
Africa the most, not many studies have been conducted on the definitions of AIDS restriction
Table 3. Association between 3 single loci and HIV-1 Status, Based on Additive, Dominant and Recessive Models.
Markers Models OR 95% CI p-Value
rs6001417 C/C (referent), C/G, G/G, additive 1.68 1.78–2.40 <0.01
rs6001417 C/C vs. C/G & G/G, dominant 1.22 0.86–1.72 0.28
rs6001417 T/T vs. C/C & C/T, recessive 0.60 0.41–0.88 <0.01
rs8177832 A/A (referent), A/G, G/G additive 1.65 1.15–2.37 <0.01
rs8177832 A/A vs. A/G &G/G, dominant 1.18 0.84–1.67 0.36
rs8177832 G/G vs. A/A &A/G, recessive 0.61 0.41–0.90 0.01
rs35228531 C/C (referent), C/T, TT, additive 1.11 0.68–1.78 0.7663
rs35228531 C/C vs. C/T & T/T, dominant 1.73 1.26–2.38 <0.001
rs35228531 T/T vs. C/C & C/T, recessive 0.48 0.31–0.76 0.001
doi:10.1371/journal.pone.0146386.t003
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genes on native populations, in which genotype frequencies depend on ethnic background
[15], [24]. In this study, we describe the frequency of 3 SNP genotypes and their haplotypes.
There have been very few studies on rs6001417 and rs35228531 since their identification by
Reddy et al.
Fig 1. Haploview APOBEC3G linkage disequilibrium plots for case and controls. The figures are
oriented 5’ to 3’, right to left, relative to the gene orientation on the minus strand. Fig 1a represents the LD plot
of the case pairwise D’ between markers, and Fig 1b shows the LD plot of the control pairwise D’ between
markers. Strong LD is indicated by red, while pink indicate uninformative values. LD blocks were created with
the default algorithm in the Haploview software (version 4.1) that creates 95% confidence bounds. D’ was
considered strong where 95% of the comparisons made are informative.
doi:10.1371/journal.pone.0146386.g001
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The H186R mutation of APOBEC3G has been reported in the literature to be associated
with an accelerating effect on disease progression in African Americans infected with HIV-1
subtype B at a frequency of 0.37 [15]. Furthermore, the latter effect was also reported in a
South African cohort infected with HIV-1 subtype C carrying the H186R mutation with a fre-
quency of 0.307 [16]. This polymorphism is also associated with rapid disease progression in a
population of HIV-1 subtype B infected children. In our study, this mutation occurred at a fre-
quency of 43.8% in a population infected with HIV-1 circulating recombinant forms
CRF06_cpx and CRF02_AG. The genotyping results showed that all 3 loci followed the Hardy
Weinberg Equilibrium.
Our statistical analysis revealed that the 3 loci tested did not show an association with CD4
T cell count or viral load (Data not shown). This finding in our study population of Burkina
Faso implies that the host genetic variations play a greater role in the hyper-mutations than
viral genetic variation.
The results suggest that the minor alleles G, T and G are protective against infection in
homozygotes for rs6001417, rs8177832, and rs35228531 respectively, with OR = 0.78 [95% CI:
0.63–0, 97, p = 0.022], OR = 0.61 [95% CI: 0. 41–0. 09, p = 0. 01], and OR = 0.63; [95% CI:
0.50–0.78, p = 0.00003], but these results may be due to the high linkage disequilibrium that
exists between them.
The variants of rs35228531 reduced greatly the risk of being infected with HIV-1 for the
carriers of the minor allele T in the homozygous state with an OR: 0.63 [95% CI: 0.50–0.78,
p = 0.00003] and an almost doubled risk of HIV-1 infection when the wild type allele C is present
in homozygotes, OR = 1.76 [95% CI: 1.26–2.38; p = 0.0005]. Furthermore, the genotype CC after
a multinomial logistic regression showed a tripled (3) risk of infection to HIV-1 (OR = 3.381;
Table 4. Cases and controls Haplotypes.
Haplotype Cases Controls OR CI p-Value
CAC 330 356 1,05 0,85; 1,29 0.67
CGC 35 8 5,21 2.4; 11.3 <0.001
GGC 70 52 1.6 1.1; 2.3 <0.05
GGT 187 308 0.56 0.45; 0.71 <0.001
doi:10.1371/journal.pone.0146386.t004
Fig 2. Distribution of the cases and controls haplotypes.
doi:10.1371/journal.pone.0146386.g002
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[95%CI: 1.503–7.605), p = 0.003]. The action of rs35228531 on APOBEC3G activity is still not
well defined. It is an extragenic mutation located near the 3’ region of the gene, and might there-
fore interfere with transcriptional and post-transcriptional regulation of the gene and increase its
antiviral activity. In fact, SNPs may influence promoter activity (gene expression) and thus mod-
ulate the risk of infection [25, 26].
Linkage disequilibrium was strong in all 3 pairs of loci in the Burkinabe APOBEC3G data-
set, which causes a non-independence of allele segregation. Physical proximity (about 6kb) of
these 3 loci on the gene region of APOBEC3G could explain the strong linkage in all alleles.
Linkage disequilibrium (LD) plots characterizing haplotype haplotypes blocks in APOBEC3G
are shown in Fig 1a and 1b. The association patterns differ in cases and controls, as shown in
Fig 1, a result that can be explained by the fact that the cases showed lower levels of LD com-
pared to controls.
We observed evidence for haplotype-specific associations in the HIV-1 infected group com-
pared to control subjects. In fact, for the GGT genotype there was a protective effect against
HIV-1 infection with OR = 0.56 [95% CI: 0.45–0.71; p<0.001] (Table 4). There were also asso-
ciations between the genotypes GGC (OR = 1.6 [95% CI: 1.1–2.3; p<0.05]) and CGC
(OR = 5.21 [2.4–11.3, p<0.001]), increasing the risk of infection from almost two (2) to five (5)
times by HIV-1 (Table 4). These results can be explained by the strong LD that exists between
the different loci. They can also be justified by the fact that rs6001417, rs8177832 and
rs35228531 are in linkage disequilibrium [16], which is confirmed in our study (Fig 1), there-
fore the haplotypes rs8177832, rs35228531 and rs6001417 will have the same effect.
This study shows that the variants rs8177832, rs3522851 and rs6001417 are in linkage dis-
equilibrium. Furthermore, this study demonstrates that APOBEC3G is a susceptibility gene for
HIV-1 infection in a West African population from Burkina Faso. To our knowledge, this is
the first study investigating the role of APOBEC3G variants on an HIV-1 CRF06_cpx and
CRF02_AG infection. The effect of APOBEC3G polymorphisms in our study population sug-
gests that APOBEC3G sequence variation plays a role at a biological level in the interaction of
HIV-1 and the host. The precise role of APOBEC3G and its variants in HIV-1 susceptibility
needs to be elucidated in further studies.
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